Compare Novo Nordisk A/S (NVO) vs Oatly Group AB - ADR (OTLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Oatly Group AB - ADR — how do they compare? Novo Nordisk A/S trades at $45.1 (market cap $200.69B), while Oatly Group AB - ADR trades at $12.53 (market cap $432.09M). The key difference: Novo Nordisk A/S is far larger — about 464.5× Oatly Group AB - ADR's market cap, and Novo Nordisk A/S pays a 3.98% dividend while Oatly Group AB - ADR pays none. Which is the better fit depends on your goals.
| NVO | OTLY | |
|---|---|---|
Market Cap | $200.69B | $432.09M |
Sector | Health | Consumer Staples |
52-Week High | $63.98 | $18.09 |
52-Week Low | $35.29 | $8.03 |
Enterprise Value | $215.49B | $936.50M |
Dividend Yield | 3.98% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $45.16, down 3.09% on the day, with a bearish technical outlook. The stock shows strong fundamentals, including a P/E of 11.07, net income margin of 35.35%, and consistent earnings beats. Recent news highlights the launch of Wegovy pill in Germany and positive pediatric obesity trial results, though competition with Eli Lilly remains intense.
The outlook is mixed: strong profitability and analyst buy consensus (57.9%) support upside, but technical weakness and competitive pressures pose risks. Revenue growth is steady, with 2026 projections at $329.4B, but recent trial halts for cardiovascular drugs dim diversification prospects.
Oatly (OTLY) trades at $13.52, down 3.98% today, with a bullish technical signal from a recent golden cross but bearish moving averages. Revenue growth improved to $862.46M in 2025, yet net losses persist at -$152.77M. The company raised its 2026 revenue outlook after Q2 results, driving positive sentiment from news outlets like Seeking Alpha on July 22, 2026.
Outlook hinges on margin expansion and path to profitability, with risks from high debt and cash burn. Analysts are mixed (44% buy, 50% hold), reflecting optimism on operational turnaround but caution on financial sustainability. Key catalysts include product innovation and market expansion, though negative cash flows and equity erosion pose significant investor risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Oatly Group AB - ADR
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, Icecreams, among others. It caters to Sweden, Germany, United Kingdom, Netherlands, North America, Finland, and other markets.
Read more on OTLY →
